Ascendis Pharma A/S growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +135.3%
EBITDA: +105.1%
EBIT: +97.9%
EPS: +240.7%
Free cash flow: +119.1%
Operating cash flow: +126.3%

Forward estimates

Revenue: +89.8%
EBITDA: —
EPS: -18.9%

Three-year CAGR

Revenue: +138.2%
EBITDA: +62.1%
EBIT: +53.0%
Net income: +42.1%
EPS: +44.6%
Free cash flow: +114.2%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.